Clear All
720 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
Q2054 Lisocabtagene maraleucel Breyanzi Immunotherapy CAR-T CD19 No 2021 Sep 27, 2021 In Use
NA Ruxolitinib Jakafi 25 mg Chemotherapy Enzyme Inhibitor JAK 1/2 Yes 2011 In Use
NA Ruxolitinib Jakafi 20 mg Chemotherapy Enzyme Inhibitor JAK 1/2 Yes 2011 In Use
S0178 Lomustine Ceenu, Gleostine 10 mg Chemotherapy Alkylating Agent Nitrosourea Yes 1976 Jan 1, 2002 In Use
NA Cedazuridine and Decitabine Inqovi 100mg, 35mg Chemotherapy Antimetabolite Pyrimidine Analog + CDA Inhibitor Yes 2020 In Use
J9999 Chemotherapy - non specific Not otherwise classified, antineoplastic drugs NA Chemotherapy No In Use
J8999 Chemotherapy - non specific Prescription drug, oral, chemotherapeutic NOS NA Chemotherapy Yes In Use
S0172 Chlorambucil Leukeran 2 mg Chemotherapy Alkylating Agent Nitrogen Mustard Yes 1957 Jan 1, 2002 In Use
C9084 Loncastuximab tesirine Zylonta 0.1mg Immunotherapy Drug Antibody Conjugate CD19 No 2021 Sep 27, 2021 Mar 25, 2022 In Use
C9253 Temozolomide Temodar 1 mg Chemotherapy Alkylating Agent Tetrazine No 1999 Jan 1, 2010 In Use
J9296 Pemetrexed (Accord) Pemetrexed (Accord) 10mg Chemotherapy Antimetabolite Folic Acid Analog No 2022 Mar 17, 2023 In Use
J9322 Pemetrexed (Bluepoint) Pemetrexed (Bluepoint) 10mg Chemotherapy Antimetabolite Folic Acid Analog No 2022 Jul 11, 2023 In Use
J3489 Zoledronic acid Zometa (4 mg/5 ml) 1 mg Ancillary Therapy Bisphosphonate No 2001 Jan 1, 2014 In Use
J2353 octreotide sandostatin LAR 1 mg Hormonal Therapy Somatostatin Analog No 1998 Jan 1, 2004 In Use
NA Pazopanib Votrient 200 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR,KIT, Lck, FMS Yes 2009 In Use
J9340 Thiotepa Tepadina 15 mg Chemotherapy Alkylating Agent Nitrogen Mustard /Ethylenimine No 1959 Jan 1, 1984 In Use
J3240 Thyrotropin alfa Thyrogen 0.9 mg /1.1 ml vial Hormonal Therapy Thyroid Stimulating Hormone No 1998 Jan 1, 2003 In Use
J9266 Pegaspargase Oncaspar unspecified Chemotherapy Miscellaneous Agent Enzyme No 1994 Jan 1, 1996 In Use
A9545 Tositumomab Bexxar, Iodine i-131 Tositumomab, therapeutic Per treatment dose Immunotherapy, Radiopharmaceutical Radioimmunotherapy CD20 No 2003 2014 Jan 1, 2006 In Use
NA Umbralisib Ukoniq 260.2mg Chemotherapy Enzyme Inhibitor PI3Kδ, CK1ε, ABL1, CXCL12, CCL19 Yes 2021 In Use
J9202 Goserelin Acetate Zoladex 3.6 mg Hormonal Therapy GnRH Agonist No 1989 Jan 1, 1997 In Use
BA Belzutifan Welireg 40mg Chemotherapy Miscellaneous Agent HIF-2 alpha Yes 2021 In Use
NA Regorafenib Stivarga 40 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR,KIT,RET,TIE2,DDR2,TrkQ,RAF,BRAF,SAPK2, PTK, Abl Yes 2012 In Use
NA Relugolix Orgovyx 120mg Hormonal Therapy Androgen Receptor Inhibitor GnRH Receptor Antagonist Yes 2020 In Use
J9345 Retifanlimab-dlwr Zynyz 1mg Immunotherapy Checkpoint Inhibitor PD-1 No 2023 Aug 28, 2023 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.